ULA Vulcan rocket achieves liftoff in national security launch
Aug. 12 (UPI) -- United Launch Alliance successfully launched one of its Vulcan Centaur rockets into orbit Tuesday, demonstrating the viability of a newly developed technology for the U.S. military's space capabilities.
The rocket at Cape Canaveral Space Force Station in Florida at 8:56 p.m. EDT Tuesday. It's the third launch ever of the company's Vulcan rockets and the first time it was used for a national security mission, referred to as United States Space Force (USSF)-106, reported Spaceflight Now.
"This is literally the mission that drove the design of the vulcan," Tori Bruno, president and CEO of ULA, said during the company's livestream leading up to the launch.
The video showed the rocket lifting off and its bright glare cutting through the Florida night sky.
LIFTOFF of the United Lunch Alliance Vulcan rocket, continuing ULA's soaring legacy in national security space launch!
Launch info: https://t.co/ZNSovZl0Lu Photos: https://t.co/QbM4zpZ6I1 pic.twitter.com/vU4hw4F0PI— ULA (@ulalaunch) August 13, 2025
The mission centers on the Vulcan delivering classified payloads as well as a Navigation Technology Satellite-3 system into orbit. The NTS-3 is operated by Air Force Research Laboratory and will be used to shield GPS technology and critical infrastructure from jamming, the deliberate jamming of signals.
ULA said in an X post earlier that it would deploy its mission at geosynchronous orbit, which is more than 22,000 miles above the Earth's surface and more closely aligns with its rotation.
The Vulcan's launch means an end to the U.S.'s reliance on Russian-made rockets as mandated by Congress as well as additional capabilities for Space Force, according to a press release. The launch is the first integrated navigation satellite experiment in nearly 50 years.
Col. Jim Horne, US Space Force mission director, during a media call Monday called the launch "a historic point in our program history," reported Signal, a publication of the Armed Forces Communications and Electronics Association.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
an hour ago
- Medscape
Tibremciclib for Advanced Breast Cancer: Is It Worth It?
Adding the novel CDK4/6 inhibitor tibremciclib (Betta Pharmaceuticals) to second-line fulvestrant significantly extended progression-free survival (PFS) in patients with HR-positive/HER2-negative advanced breast cancer, but with the tradeoff of increased toxicity, new data suggest. Compared with fulvestrant alone, the combination prolonged median PFS for these patients by 11 months, according to results from the phase 3 TIFFANY trial. However, similar to existing CDK4/6 inhibitors, the tibremciclib-fulvestrant combination added to treatment side effects — including substantially higher rates of diarrhea, hematologic toxicities, and hypokalemia. The authors of the analysis, published in JAMA Oncology , described the toxicities as "manageable," emphasizing that few patients stopped treatment because of them. Study author Xichun Hu, MD, of Fudan University Shanghai Cancer Center, told Medscape Medical News that tibremciclib compares favorably with other CDK4/6 inhibitors in terms of dose reduction and discontinuation rates. However, Hu noted, that's based on cross-trial comparisons, which have to be interpreted with caution. Kathy Miller, MD, who was not involved in the trial, had a similar take. 'Toxicity actually looks similar to ribociclib and palbociclib, with primarily myelosuppression and little non-heme toxicity,' Miller, of the Melvin and Bren Simon Comprehensive Cancer Center at Indiana University, told Medscape Medical News. Tibremciclib plus fulvestrant was recently approved in China for HR-positive/HER2-negative advanced breast cancer following results from the trial, but the combination has yet to be approved in the US. The Benefits vs the Risks In the trial, Hu and colleagues studied the safety and efficacy of the new agent among patients from 69 centers in China who had experienced progression while on endocrine therapy and had received no more than one line of chemotherapy. A total of 274 patients were randomized (2:1) to receive either tibremciclib (400 mg orally, once daily) or placebo plus fulvestrant until disease progression, death, or treatment discontinuation over a median follow-up of 13 months. Eighty patients (43.5%) in the tibremciclib arm and 64 (71.1%) in the placebo arm experienced a PFS event (disease progression or death). Tibremciclib plus fulvestrant significantly improved PFS to 16.5 months versus 5.6 months with fulvestrant alone, reducing the risk of progression by 63% (hazard ratio [HR], 0.37; P < .001). As for safety, adverse events were higher in the treatment arm. The most common treatment-emergent adverse events were diarrhea (79.3% in the tibremciclib arm vs 13.3% in placebo arm), neutropenia (75.5% vs 15.6%), leukopenia (73.9% vs 16.7%), and anemia (69% vs 21.1%). Nausea and vomiting were also more common with tibremciclib, at 37% and 40.2%, respectively — versus 18.9% and 11.1% in the placebo group. Most often, those adverse events were grade 1 or 2. However, 50.5% of patients in the tibremciclib group had a grade 3 or higher treatment-emergent adverse event, versus 21.1% in the placebo group. The most common were neutropenia (15.2% vs 5.6%), anemia (12.0% vs 4.4%), and hypokalemia (12% vs 0%). Hypokalemia was often due to diarrhea and was managed with electrolyte monitoring and potassium supplementation, Hu said. One-third of patients in the tibremciclib arm developed hypertriglyceridemia (5.4% grade 3 or higher) — a rate higher than that seen with other CDK4/6 inhibitors. Cases were managed with lipid-lowering agents such as atorvastatin. More patients on tibremciclib experienced dosing interruptions due to adverse events (54% vs 23%), and dose reductions were also more common with the combination therapy (18.5% vs 4.4%). However, only four patients (all in the tibremciclib arm) discontinued treatment due to side effects. Overall, the adverse event profile of tibremciclib lines up with that of other CDK4/6 inhibitors and comes with better PFS, Hu said, noting that "the benefit-risk balance of tibremciclib plus fulvestrant appears highly favorable." In TIFFANY, the authors note d that cases of neutropenia and leukopenia were numerically lower than in trials of abemaciclib, dalpiciclib, and palbociclib plus fulvestrant. According to Hu, tibremciclib is structurally different from other drugs in its class, with a greater selectivity for CDK4 and less inhibition of CDK6 and CDK9, which may reduce the incidence of neutropenia as well as severe diarrhea. Plus, the PFS improvement seen in TIFFANY was greater, Hu said. Pa lbociclib in PALOMA-3 showed a median PFS of 9.5 months vs 4.6 months for fulvestrant alone (HR, 0.46); abemaciclib in MONARCH led to a PFS of 11.5 months vs 5.6 months (HR, 0.38, a Chinese population); and dalpiciclib in DAWNA-1 achieved 16.6 months vs 7.2 months (HR, 0.50, also in Chinese patients). While these are cross-trial comparisons, it's still unclear exactly how tibremciclib stacks up against other drugs in its class (including its impact on overall survival). The authors also caution that, because the trial exclusively enrolled Chinese patients without prior CDK4/6 inhibitor exposure, the findings may not be generalizable to broader populations, particularly in regions like North America and Europe. Miller pointed to the generalizability question as well, noting that fulvestrant monotherapy is typically not the standard of care in the US and other Western countries. 'This [study] joins a long list of second-line endocrine studies that show drug activity but don't compare to standard of care and don't really tell us how to best use the drug,' Miller said.
UPI
4 hours ago
- UPI
SpaceX launches Starlink satellites from Florida, California
SpaceX launched a new batch of Starlink satellites from California and Florida to continue the growth of its broadband internet service. Photo by Joe Marino/UPI | License Photo Aug. 14 (UPI) -- SpaceX launched new batches of Starlink satellites from California and Florida to continue the growth of its broadband Internet service. The California launch lifted off at 1:05 a.m. EDT from Space Launch Complex 4 East at Vandenberg Space Force Base on Thursday, it carried 24 more Starlink Satellites. It took roughly an hour for the upper stage to deploy its satellites after it left Earth. The launch was SpaceX's 98th Falcon 9 mission in 2025 and now there are 8,100 active satellites out of the nearly 9,400 launched in 2018. Meanwhile, the Florida launch from Cape Canaveral Space Force Station took off at 8:29 a.m. EDT on Thursday with a batch of 28 V2 mini satellites, this was also the 69th orbital launch from Florida this year. The launch had a 90% chance of favorable weather.
20 hours ago
Stargazers dazzled as spirals of light appear in night sky
Stargazers on the lookout for the Perseid meteor shower were treated to an extra nighttime spectacular on Tuesday night as spirals appeared in the sky along the East Coast. The unusual light show -- which appeared to show circling lights in the heavens -- was on display after multiple rocket launches. Videos began circulating online in several states, including Maryland, New York, New Jersey, Tennessee, Illinois, Ohio and Nebraska, after 9 p.m. ET Tuesday, social media posts show. ABC Philadelphia station WPVI began receiving calls and messages from viewers around 10:30 p.m. to report the phenomenon, the station reported. The spiraling lights seemed to appear "out of nowhere," Blake Brown, who witnessed the dazzling display from Algonquin, Illinois, while watching for the meteor shower, told ABC News. The majority of the spiraling light sightings likely stemmed from the launch of Ariane 6, said Jonathan C. McDowell, an astrophysicist for the Harvard-Smithsonian Center for Astrophysics. That rocket lifted off from the Guiana Space Centre at Europe's Spaceport in Kourou, French Guiana, at about 8:37 p.m. ET, according to Eumetsat, a European operational satellite agency for monitoring weather. Ariane 6, about 196-feet tall, has the ability to launch both heavy and light payloads for applications such as Earth observation, telecommunication, meteorology, science and navigation, according to the European Space Agency. The appearance of the spirals in the sky was likely the result of the upper stage of the rocket tumbling as it underwent a disposal rocket firing at the end of the launch, McDowell told ABC News. The spiral light occurs when reflection from sunlight interacts with the frozen plume of fuel from the exhaust of rockets. "It's a nice, perfect spiral because it's way out in space with no air to distort the shape," McDowell said. Tuesday's launch, which brought a weather satellite to orbit, is the third-ever mission for the powerful rocket, according to Another rocket, the Vulcan Centaur Rocket, successfully lifted off from the Cape Canaveral Space Force Station in Florida at 8:56 p.m. ET, according to the United Launch Alliance. The 202-foot rocket was carrying a pair of experimental navigation satellites on behalf of the United States Space Force's first-ever mission, according to "The Vulcan launched east and went to a high orbit, and was still coasting upward [without the rocket firing] when the spiral was seen," McDowell said. "If people in Florida saw something at 9:37, 9:45 pm ET, that could have been the Vulcan."
